{
    "clinical_study": {
        "@rank": "83803", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given at variable dose for three months. Subjects undergo brain imaging with O-15 radiolabelled water during exposure to reminders of childhood abuse before and after treatment."
            }, 
            {
                "arm_group_label": "Paroxetine", 
                "arm_group_type": "Experimental", 
                "description": "Paroxetine given in a double-blind fashion at a variable dosage of 10-40 mg per day over three months, with positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water before and after treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effects of the medication paroxetine on symptoms\n      of posttraumatic stress disorder (PTSD) and the brain in women with a history of PTSD\n      related to childhood abuse. The hypothesis is that paroxetine will result in an improvement\n      in PTSD symptoms accompanied by changes in brain functional response to reminders of\n      childhood trauma."
        }, 
        "brief_title": "Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "PTSD", 
        "condition_browse": {
            "mesh_term": [
                "Stress Disorders, Post-Traumatic", 
                "Stress Disorders, Traumatic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects  meet criteria for current PTSD as determined by the Structured Clinical\n             Interview for DSMIV (SCID) interview for PTSD  and the Clinician Administered PTSD\n             Scale (CAPS) and have a score of greater than 60 on the CAPS\n\n          -  history of penetrative sexual abuse which occurred once a month or more, for a period\n             of greater than a year at some time between the ages of 4-13, as assessed by the\n             Early Trauma Inventory (ETI)\n\n          -  are free of psychotropic medication for four weeks before the study (subjects will\n             not be taken off of medication for the purpose of the study).\n\n          -  Non-PTSD subjects will be included based on the same criteria with the exception that\n             they do not meet criteria for PTSD.\n\n        Exclusion Criteria:\n\n          -  a history of shrapnel or other foreign bodies which would preclude MRI scanning\n\n          -  meningitis\n\n          -  traumatic brain injury\n\n          -  neurological disorder or organic mental disorder\n\n          -  history of loss of consciousness\n\n          -  alcohol abuse or substance abuse or dependence based on the SCID within the past 24\n             months\n\n          -  positive pregnancy test as measured by a serum beta-HCG or urine pregnancy test on\n             the morning of the PET scan. Women will be counseled about the risks of pregnancy\n             during the course of the study\n\n          -  current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia,\n             based on the SCID\n\n          -  a history of serious medical or neurological illness, such as cardiovascular,\n             gastrointestinal, hepatic, renal, neurologic or other systemic illness\n\n          -  evidence of a major medical or neurological illness on physical examination or as a\n             result of laboratory studies (CBC, BUN, creatinine, blood sugar, electrolytes, liver\n             and thyroid function tests, urinalysis, and EKG)\n\n          -  positive urine toxicology screen\n\n          -  history of ongoing violence such as domestic abuse as measured by the ETI-lifetime\n\n          -  post-menopausal status as measured by menstrual history.\n\n          -  Non-PTSD subjects will additionally be excluded with current major depression or\n             other major psychiatric disorder based on the SCID."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681849", 
            "org_study_id": "IRB00000857", 
            "secondary_id": "R01MH56120"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo", 
                    "Paroxetine"
                ], 
                "description": "Following the double blind phase, subjects are treated with open label paroxetine at a variable dosage of 10-40 mg followed by PET imaging of the brain with O-15 radiolabelled water.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "sugar pill manufactured to look like paroxetine"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Paroxetine"
                ], 
                "description": "Following the double blind phase, subjects are treated with open label paroxetine at a variable dosage of 10-40 mg followed by PET imaging of the brain with O-15 radiolabelled water.", 
                "intervention_name": "Paroxetine", 
                "intervention_type": "Drug", 
                "other_name": "Paxil"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paroxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PTSD", 
            "childhood abuse"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "link": {
            "description": "Home page of Emory Clinical Neuroscience Research Unit", 
            "url": "http://userwww.service.emory.edu/~jdbremn/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30306"
                }, 
                "name": "Emory University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PTSD symptoms as measured with the Clinician Administered PTSD Scale (CAPS)", 
            "measure": "PTSD symptoms", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681849"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Emory University", 
            "investigator_full_name": "J. Douglas Bremner, M.D.", 
            "investigator_title": "Professor of Psychiatry and Radiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Changes in brain functional response to reminders of childhood abuse.", 
            "measure": "Brain Function", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Emory University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Emory University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}